Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy

Metastatic Melanoma – A Review of Current and Future Treatment Options

(2015) E Maverakis et al.   ACTA DERMATO-VENEREOLOGICA

The Role of Anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date

(2015) Katy K. Tsai et al.   DRUGS

Gauging the Long-Term Benefits of Ipilimumab in Melanoma

(2015) Antoni Ribas et al.   JOURNAL OF CLINICAL ONCOLOGY

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

(2015) Robert H.I. Andtbacka et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

(2015) Michael A. Postow et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immune checkpoint modulation: Rational design of combination strategies

(2015) Dmitriy Zamarin et al.   PHARMACOLOGY & THERAPEUTICS

Clinical Acquired Resistance to RAF Inhibitor Combinations in BRAF-Mutant Colorectal Cancer through MAPK Pathway Alterations

(2015) L. G. Ahronian et al.   Cancer Discovery

Phase 2 Study of Intralesional PV-10 in Refractory Metastatic Melanoma

(2014) John F. Thompson et al.   ANNALS OF SURGICAL ONCOLOGY

Biosafety of Gene Therapy Vectors Derived From Herpes Simplex Virus Type 1

(2014) Filip Lim et al.   CURRENT GENE THERAPY

Intralesional therapy for metastatic melanoma

(2014) Sarah Sloot et al.   EXPERT OPINION ON PHARMACOTHERAPY

Combinatorial Approach to Treatment of Melanoma

(2014) Michelle T. Ashworth et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes

(2014) Christopher A. Barker et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

(2014) Caroline Robert et al.   LANCET

Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses

(2014) B. Weide et al.   Cancer Immunology Research

Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma

(2014) F. S. Hodi et al.   Cancer Immunology Research

Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression

(2014) Damya Laoui et al.   Frontiers in Immunology

Treating advanced melanoma: current insights and opportunities

(2014) Michael Tronnier et al.   Cancer Management and Research

Final planned overall survival (OS) from OPTiM, a randomized Phase III trial of talimogene laherparepvec (T-VEC) versus GM-CSF for the treatment of unresected stage IIIB/C/IV melanoma (NCT00769704)

(2014) Robert HI Andtbacka et al.   Journal for ImmunoTherapy of Cancer

Current status of granulocyte–macrophage colony-stimulating factor in the immunotherapy of melanoma

(2014) Howard L Kaufman et al.   Journal for ImmunoTherapy of Cancer

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

(2014) Mizuki Nishino et al.   Journal for ImmunoTherapy of Cancer

Pharmacological Modulation of Anti-Tumor Immunity Induced by Oncolytic Viruses

(2014) Nicole E. Forbes et al.   Frontiers in Oncology

Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T-Cell Rejection Function in Tumors

(2013) J. Duraiswamy et al.   CANCER RESEARCH

The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma

(2013) Howard L. Kaufman et al.   Nature Reviews Clinical Oncology

Challenge of Primary Tumor Management in Patients With Stage IV Colorectal Cancer

(2012) George J. Chang   JOURNAL OF CLINICAL ONCOLOGY

Oncolytic virotherapy

(2012) Stephen J Russell et al.   NATURE BIOTECHNOLOGY

Dissecting Therapeutic Resistance to RAF Inhibition in Melanoma by Tumor Genomic Profiling

(2011) Nikhil Wagle et al.   JOURNAL OF CLINICAL ONCOLOGY

Thunder and Lightning: Immunotherapy and Oncolytic Viruses Collide

(2011) Alan Melcher et al.   MOLECULAR THERAPY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Phase I/II Study of Oncolytic HSVGM-CSF in Combination with Radiotherapy and Cisplatin in Untreated Stage III/IV Squamous Cell Cancer of the Head and Neck

(2010) K. J. Harrington et al.   CLINICAL CANCER RESEARCH

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

(2010) Howard L Kaufman et al.   Future Oncology

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Local and Distant Immunity Induced by Intralesional Vaccination with an Oncolytic Herpes Virus Encoding GM-CSF in Patients with Stage IIIc and IV Melanoma

(2009) Howard L. Kaufman et al.   ANNALS OF SURGICAL ONCOLOGY

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

Phase II Clinical Trial of a Granulocyte-Macrophage Colony-Stimulating Factor–Encoding, Second-Generation Oncolytic Herpesvirus in Patients With Unresectable Metastatic Melanoma

(2009) Neil N. Senzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Serum Vascular Endothelial Growth Factor and Fibronectin Predict Clinical Response to High-Dose Interleukin-2 Therapy

(2009) Marianna Sabatino et al.   JOURNAL OF CLINICAL ONCOLOGY